touchLearning Activities
Education, Conference Coverage and Articles
Recent omaveloxolone updates include progress in the phase 3 BRAVE study, development of a liquid-ready formulation and evolving reimbursement discussions across multiple regions Phase 3 BRAVE study advances pediatric development in Friedreich’s ataxia Biogen is continuing to expand the clinical development ...
Your clinical career is shaped not only by what you know, but by who helps you navigate what comes next. Join us for the final episode in our mini-series exploring non-clinical skills that can help you thrive in your clinical ...
Leading experts share their perspectives on the most important therapeutic and treatment updates at AAN 2026 and discuss how these findings may shape the future of neurologic care At American Academy of Neurology (AAN) Annual Meeting, Chicago, IL, USA, April 18–22, 2026, major ...
Emerging data from AAN 2026 across neuroimmunology, epilepsy, neuromuscular disease, movement disorders and neuroinfectious disease highlighted the continued evolution of neurology toward more precise, personalized and mechanism-driven care. The American Academy of Neurology (AAN) Annual Meeting, Chicago, IL, USA, from April 18–22, 2026, ...
Findings from AAN 2026 highlight a potential “survival paradox” associated with GLP-1 analogue use in older adults with diabetes At American Academy of Neurology 2026, Isaac Thorman (New York Medical College, Valhalla, NY, USA) presented new real-world data exploring the relationship between ...
Medics for Rare Disease launches campaign highlighting the “five-year wait” faced by patients with rare diseases Medics for Rare Disease has launched a new awareness campaign highlighting the significant impact of delayed diagnosis in rare disease, with touchNEUROLOGY proud to ...
ESOC 2026 highlights: Blood pressure management, neuroprotection and widening inequalities shape stroke discussions in Maastricht #VoiceOfStroke [caption id="attachment_101685" align="alignright" width="300"] © European Stroke Organisation #VoiceOfStroke[/caption] At the 12th European Stroke Organisation Conference 2026, late-breaking clinical trial data and population-level analyses ...
Kathy Costello, CMSC, and Bonnie Blain, IOMS, join together to discuss four decades of innovation in MS, from MRI and DMTs, to emerging neuroprotective strategies and personalized care. As the Consortium of Multiple Sclerosis Centers (CMSC) celebrates its 40th ...
New findings highlight the importance of functional antiviral immunity, beyond lymphocyte expansion alone, in progressive multifocal leukoencephalopathy. At American Academy of Neurology 2026, Dr Yair Mina (Staff Clinician, Experimental Immunotherapeutics Unit, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, ...
Prof. Peter Hedera discusses the potential of tiomolibdate choline to improve neurologic outcomes and reduce deterioration risk in Wilson disease. Neurologic worsening remains one of the greatest treatment challenges in Wilson disease, where delayed diagnosis and paradoxical deterioration during therapy ...
Findings from the HOPE-3 phase 3 trial demonstrate positive effects on upper limb function and cardiac outcomes in Duchenne muscular dystrophy New phase 3 data presented at the American Academy of Neurology Annual Meeting 2026 highlight the potential of deramiocel as a novel ...
New international data support rapid aquaporin-4 antibody testing to improve earlier diagnosis and access to care in NMSOD Accurate and timely antibody testing remains central to improving outcomes in neuromyelitis optica spectrum disorder (NMOSD), where early diagnosis can help prevent ...
New X-TOLE2 findings highlight the potential of azetukalner in treatment-resistant focal epilepsy Despite a growing number of available therapies, many people with Focal epilepsy continue to experience uncontrolled seizures, highlighting the ongoing need for more effective and better tolerated treatment ...
Dr Micah Luftig discusses the implications for clinical risk stratification and early intervention, and how EBV-targeted strategies may shape future therapeutic approaches Growing evidence has positioned Epstein–Barr virus (EBV) as a central factor in the development of multiple sclerosis (...
The late-breaking science sessions at AAN Annual Meeting 2026, Chicago, IL, USA brought together a wide range of pivotal and practice-shaping data spanning rare disease, neuroimmunology, headache, epilepsy, neurodegeneration and neuromuscular medicine. Several presentations reported positive phase III findings, while others ...
Prof. Michael Levy highlights the first positive phase 3 trial in MOGAD and what it could mean for future standards of care. Relapse prevention remains one of the greatest unmet needs in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), where recurrent inflammatory ...
Six key oral presentations from this year’s ADI meeting on diagnosis, therapies and innovation in care Conference coverage | Held from 14–16 April, the 37th Global Conference of Alzheimer’s Disease International (ADI), Lyon, France, brought together global expertise and lived ...
touchNEUROLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
